SAN DIEGO – Sept. 22, 2021 – Tryp Therapeutics Inc. (CSE:TRYP)(OTCQB:TRYPF)(FRA:8FW)(“Tryp”), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, announced today that it has submitted an Investigational New Drug (“IND”) application to the U.S. Food and Drug Administration (“FDA”) to evaluate its clinical candidate, TRP-8802, in a Phase 2a study for the treatment of patients with eating disorders.
The trial is being conducted with Jennifer Miller, M.D., from the University of Florida and will evaluate the Company’s oral formulation of synthetic psilocybin, TRP-8802, in combination with psychotherapy. The IND application ...
Read The Full Article On MicroSmallCap.com
Get early insight on hidden secret gems on MicroSmallCap . Follow Crypto, Mining, Cannabis and Energy stocks and get free research reports here .
All content provided by MicroSmallCap is subject to our Terms Of Use and Disclaimer .
For further details see:
Tryp Therapeutics Submits IND Application For Phase 2a Clinical Trial In Eating Disorders